Corium to Join NASDAQ Biotechnology Index
December 12 2017 - 7:30AM
Corium International, Inc. (Nasdaq:CORI), a commercial-stage
biopharmaceutical company focused on the development, manufacture
and commercialization of specialty transdermal products, today
announced that it has been selected for addition to the NASDAQ
Biotechnology Index (NBI) as part of the NBI’s annual re-ranking,
which will become effective prior to market open on Monday,
December 18, 2017.
“2017 has been a year of important progress for Corium and our
lead proprietary once-weekly patch for Alzheimer’s disease,
Corplex™ Donepezil,” said Peter D. Staple, President and Chief
Executive Officer of Corium. “We are pleased to have that
progress further recognized by our inclusion in the NASDAQ
Biotechnology Index.”
The NASDAQ Biotechnology Index contains securities of
NASDAQ-listed companies classified according to the Industry
Classification Benchmark as either Biotechnology or Pharmaceuticals
that also meet other eligibility criteria. Companies in the NBI
must meet certain requirements, including minimum market
capitalization and average daily trading volume, among other
criteria. The NASDAQ Biotechnology Index is re-ranked annually and
forms the basis for a number of Exchange Traded Funds (ETFs),
including the iShares NASDAQ Biotechnology ETF. For more
information about the NASDAQ Biotechnology Index visit
https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Corium
Corium International, Inc. is a commercial-stage
biopharmaceutical company focused on the development, manufacture
and commercialization of specialty pharmaceutical products that
leverage the company's broad experience with advanced transdermal
and transmucosal delivery systems. Corium has multiple
proprietary programs in preclinical and clinical development,
focusing primarily on the treatment of neurological disorders, with
lead programs in Alzheimer's disease. Corium has developed
and is the sole commercial manufacturer of seven prescription drug
and consumer products with partners Mayne Pharma and Procter &
Gamble. The company has two proprietary transdermal
platforms: Corplex™ for small molecules and MicroCor®, a
biodegradable microstructure technology for small molecules and
biologics, including vaccines, peptides and proteins. In
addition to its proprietary Alzheimer’s program, the company's
late-stage pipeline includes a contraceptive patch co-developed
with Agile Therapeutics and additional transdermal products that
are being developed with other partners. For further
information, please visit www.coriumintl.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation
Reform Act of 1995, including statements regarding our proprietary
products and product candidates. Forward-looking statements
are based on management's current expectations and projections and
are subject to risks and uncertainties, which may cause Corium's
actual results to differ materially from the statements contained
herein. Further information on potential risk factors that
could affect Corium's business and its results are detailed in
Corium's Quarterly Report on Form 10-Q for the quarter
ended June 30, 2017, filed with the Securities and
Exchange Commission (SEC) on August 11, 2017, and other reports as
filed from time to time with the SEC. Undue reliance
should not be placed on forward-looking statements, especially
guidance on future financial or operating performance, which speaks
only as of the date they are made. Corium undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
they were made or to reflect the occurrence of unanticipated
events.
Corplex™ and MicroCor® are registered trademarks of Corium
International, Inc.
Source: Corium
Investor and Media Contact:SMP CommunicationsSusan M.
Pietropaolosusan@smpcommunications.com(201) 923-2049
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From Mar 2024 to Apr 2024
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From Apr 2023 to Apr 2024